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Abstract
Background: Valproic acid (VPA) is often used to control pain in HIV-related neuropathy.
However, the effect of VPA on cognitive functions in advanced HIV-infected individuals is largely
unknown. A recent study would suggest that it may have a neuroprotective effect, the doses used
were low and the observation period short.
Methods: We used a well studied HIV-infected cohort assessed for a median of 15 (range 6–27
months) to determine whether individuals who were receiving VPA showed any cognitive benefits.
Multiple regression procedures allowed us to control for the effects of HAART and HIV disease
status as well as numbers of visits and variation in VPA intake over-time.
Results: We found a negative effect of VPA (mean dose of 850 mg/d for 18 months on average;
range 6–27 months) on cognitive performance in eight advanced HIV-infected individuals compared
to 32 advanced HIV-infected individuals on no VPA who had comparable neuropsychological
performance at baseline. Control for plasma HIV viral load provided similar results.
Conclusion: Our results suggest that further studies of VPA in advanced HIV-infection should
cautiously include high doses over prolonged periods of at least 18 months in order to more
accurately determine whether the posited neuroprotective benefit of VPA still occurs or whether
it is replaced by toxicity.
Background
There is now some evidence that despite the introduction
of highly active antiretroviral therapy (HAART), HIV-asso-
ciated neurocognitive disorders remains common [1].
Moreover, with longer survival, HIV-infected individuals
require complex management of co-morbid neurological
diseases. Sensory neuropathy is the most frequent neuro-
logical complication of advanced HIV-infection and Valp-
roic acid (VPA) is often used to control the associated pain
[2]. In a small proportion of HIV-infected individuals VPA
is prescribed to control HIV-related epilepsy [2]. The effect
of VPA on neurocognitive functions in advanced HIV-
infected individuals is largely unknown.
In a healthy population, it has been shown that VPA
causes only transient and very mild or no cognitive defi-
cits [3,4]. But, these results are derived from short-term
studies and the long-term effects have not been thor-
oughly investigated. Moreover, it has been suggested that
VPA may be associated with more cognitive slowing due
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potentiation of gamma-aminobutyric acid (GABA) inhib-
itory neurotransmission [5]. This may be especially rele-
vant to patients with HIV-associated neurocognitive
impairment where cognitive slowing is one of the cardinal
features.
However, a recent clinical study suggests that there may be
a neuroprotective effect of VPA as an adjunctive therapy to
antiretroviral treatment. Using a 10-week placebo control-
led study, the authors found a non-significant trend for
better cognitive functioning in the VPA group (250 mg
twice a day) on cognitive function in advanced HIV-
infected individuals [6]. This is consistent with results of
in vitro studies showing a neuroprotective effect of VPA in
a murine model of HIV-1 encephalitis [7]. While these
results are potentially important, several methodological
issues render their interpretation difficult. The effect of
VPA was only observed over the short-term in a small
group, while HAART duration and number of neuroactive
drugs in the HAART regimen were not documented. In
addition, the effect of HAART was not investigated in the
analyses [8].
We have been investigating the effects of HAART on cog-
nitive function in a well studied HIV-infected cohort stud-
ied over a long period of time [9]. Given the potential
importance of the VPA finding in the Schifitto et al. study
[6], we used our observational study cohort to determine
whether individuals who were receiving VPA showed any
cognitive benefits, while accounting for the effects of
HAART and HIV disease status.
Methods
Subjects
The cohort of advanced HIV-infected individuals, partici-
pating in a longitudinal study of the neurocognitive effect
of HIV infection, was previously described in detail in
Cysique et al. [1,9] Among 101 HIV-infected individuals
with stage C3 HIV disease, 81 came for a second visit at six
months and at that time, seven HIV-infected individuals
were treated with VPA (average of 850 mg/d for 18
months; range 6–27 months) for HIV-related painful neu-
ropathy and one for HIV-related epilepsy. Patients had
been on VPA for at least three months before enrolment.
At the time of assessment, all had neuropathy and epi-
lepsy symptoms under control as assessed by an experi-
enced neurologist (BJB). Five of these individuals came
for a third visit at 15 months after baseline and four for a
fourth visit at 27 months after baseline. All were on VPA
at session 2 (8/8); 3 at session 3 (3/5) and, 2 at session 4
(2/4). Continuation or discontinuation of treatment was
related to the clinical assessment of neuropathy symp-
toms. The individual with HIV epilepsy came back at one
follow-up only (see also Table 1).
In order to adjust for baseline neuropsychological per-
formance between the individuals on and off VPA, we
selected a sub-group of the individuals who were not
receiving VPA and who had comparable neuropsycholog-
ical performance. To accomplish this, we computed a
summary z-score corrected for age and education (sum-
mary of 14 individuals neuropsychological tests, see [1,9]
for additional information) and defined the inter-quartile
performance range in the group on VPA (i.e., z-summary
score = -0.49 to -1.58). Forty individuals off VPA per-
formed at baseline within this defined range and were
used in the following analyses. Consequently, there was
no difference in baseline performance between the indi-
viduals on and off VPA (p = .58).
At baseline, the eight subjects receiving VPA did not differ
from the 32 individuals off VPA in terms of age (48.3 years
old ± 13 versus 51.9 ± 9 years old, respectively), education
(13.8 years ± 5 versus 13.6 years ± 3, respectively), HIV
duration (10.8 years ± 5.4 versus 11.5 years ± 5, respec-
tively), nadir (47.5 cpy/mL ± 48 versus 90.2 cpy/mL ±
60.1, p = .06, respectively) and current CD4 (367.6 cpy/
mL ± 265.6 versus 324.5 cpy/mL ± 240.4, respectively, log
10 plasma viral load (2.3 ± 1.2 versus 3.2 ± 1.5, p = .12,
respectively), and year of 1st HAART (1996.5 in both
groups) and number of AIDS-defining illnesses (25% had
more than two AIDS-defining illnesses in the on VPA
group, while 16% had had more than two in the non VPA
group, p = .53). Across the study period the proportion of
participants for whom their HAART regimen was updated
did not differ between the groups on and off VPA. How-
ever, the eight subjects had proportionally more past HIV-
related CNS disease compared to the patients who were
not on VPA at session 2 (62.5% [5/8] versus 9.4% [3/32];
p < .01). These were five cases of mild HIV-associated
Dementia and one case of Cryptococcal Meningitis; all
had clinically resolved at least six months before study
entry (This was a criterion of exclusion/inclusion in the
original study, see [1,9] for details). Furthermore, at base-
line the individuals on VPA did not report more depres-
sive complaints than the individuals who were not on
VPA (p = .18).
Procedure
All individuals were assessed with a standard neuropsy-
chological test battery encompassing ten tests and eight
cognitive domains (learning, memory, processing speed,
attention, complex attention, motor functions, language
and, visuo-spatial abilities (See [1,9] for additional
details).
Our research conformed to the Helsinki Declaration out-
lining the principles for medical research involving
human subjects. All subjects completed an informed con-
sent form prior to study participation. In addition, thePage 2 of 6
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pital (Sydney, Australia) research committees approved
the research protocol.
Statistical Analysis
Because we were primarily interested in the cognitive
change over-time, the focus of our previous study [9], we
determined a composite reliable index of change (RCI).
The RCI method has been shown to be equivalent to more
complex regression models [10] in determining change in
cognitive function. Here we use a newly developed RCI
described in detail in Mollica, Maruff & Vance [11] and
[9]. The composite RCI was based on six neuropsycholog-
ical measures that were found to be the most sensitive to
HIV-related cognitive decline (See [9] for additional
details). Change in cognitive functions was assessed from
the individuals who returned for session 2 (32 not on VPA
and 8 on VPA). The individuals on VPA and not on VPA
were directly compared on demographic, laboratory and
clinical variables at baseline. Between-groups analyses
were conducted with Fisher's Exact Test or t-test when
appropriate.
Moreover, to account for the variability in the number of
visits and VPA intake across time, we used a multiple
regression (or Analysis of Covariance – ANCOVA) proce-
dure described by Bland [12]. This allows controlling for
these effects on the cognitive performance over-time. One
factor that varied over-time (depressive complaints)
showed a difference (p=.05) between groups at session 2
and was therefore included as covariate in the regression
model. Lastly to account for change in the HIV disease sta-
tus as well as HAART update and efficacy, we conducted
an additional ANCOVA with log plasma viral load as a
covariate.
Results
Over time, we found greater cognitive impairment in indi-
viduals on VPA (r = -0.42; p < .005). With the effect of
depressive symptomatology on cognitive performance
Table 1: demographic, clinical and laboratory characteristics of the eight HIV+ individuals at baseline and session 2
Baseline
Patients VPA HIV 
duration




VL 50 cp/mL Year of 1st 
HAART
Past HIV-CNS Depressive 
complaints
1.00 1 11.00 90.00 580.00 1.69 undetectable 1996.00 1 mild
2.00 0 16.00 14.00 187.00 2.70 detectable 1996.00 1 mild
3.00 0 5.00 144.00 220.00 1.69 undetectable 1996.00 0 moderate
4.00 1 11.00 42.00 858.00 1.69 undetectable 1998.00 1 none
5.00 1 16.00 10.00 16.00 5.28 detectable 1996.00 1 moderate
6.00 1 9.00 25.00 220.00 1.69 undetectable 1997.00 0 mild
7.00 1 2.00 50.00 450.00 1.70 undetectable 2000.00 0 moderate
8.00 1 17.00 5.00 410.00 2.23 detectable 2000.00 1 none
Session 2




VL 50 cp/mL Depressive 
complaints
VPA session 3 VPA session 
4
1.00 1 683.00 1.70 undetectable moderate - -
2.00 1 204.00 2.60 detectable none 0 1
3.00 1 240.00 1.69 undetectable moderate 1 0
4.00 1 864.00 2.60 detectable none - -
5.00 1 90.00 4.91 detectable moderate - -
6.00 1 252.00 2.60 detectable severe 1 1
7.00 1 460.00 1.69 undetectable mild 1
8.00 1 260.00 1.69 undetectable severe 0 0Page 3 of 6
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statistically significant, albeit reduced (r = -0.34; p < .03).
Figure 1 illustrates the neuropsychological performance
over-time in the eight cases. When HIV disease status
(plasma viral load was used as a surrogate marker of HIV
disease and HAART efficacy) was added to the statistical
model the negative relationship between VPA and cogni-
tive function remained unchanged (i.e., r = -0.44; p <
.005).
Discussion
Over time, we found greater decline in cognitive function
in individuals who were receiving VPA at the time of their
follow-up examination (at six months, 15 months and 27
months after baseline). This decline could not be
explained by the presence of depressive complaints or by
HIV disease severity; defined by plasma viral load. Fur-
thermore, the eight patients in our cohort who were
receiving VPA were more likely to have been diagnosed
with a past HIV-related CNS diseases compared to indi-
viduals not receiving VPA. Our results support a relation-
ship between cognitive decline and VPA, although, further
study is required to determine the extent and magnitude
of this relationship. For example, if our results are repli-
cated then it is possible that the diminished cognitive
reserve arising from advanced HIV CNS pathology renders
cognitive function more susceptible to the deleterious
effect of VPA.
Importantly, in addition to comparable baseline neu-
ropsychological performance, our groups were well-
matched on demographics as well as HIV-related disease
variables reinforcing the robustness of a negative effect of
VPA on cognitive functions in advanced HIV-infected
individuals.
Contrary to previous studies in healthy [3,4] and HIV-
infected individuals [6], our study assessed the effect of
VPA on cognitive functions with higher dose of VPA and
over a longer period of time in individuals whose disease
status put them at increased risk for cognitive decline. It is
possible that due to non-randomization and no control of
the group assignment, the effect observed was an artifact
of advanced HIV-infection. While, this possibility remains
to be fully investigated, the complete results of our longi-
tudinal study are not supportive of such an interpretation
as most individuals with advanced HIV-infection had sta-
ble cognitive performance over the time period studied
here (see [9]). Our study included a small number of sub-
jects who also decreased over time, reducing the general-
Neuropsychological performance (composite RCI) in the 8 cases on VPA at the second follow-up visitFig re 1
Neuropsychological performance (composite RCI) in the 8 cases on VPA at the second follow-up visit. All cases were on VPA 
at session 2, cases 2 and 8 were off VPA at session 3 and case 3 and 8 were off at session 4. A negative composite RCI indicates 
decline.Page 4 of 6
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also included a similarly small number of individuals,
while none of their results was statistically significant.
Nevertheless, we chose to explore the VPA effect with hier-
archical regression. This statistical technique allowed us to
use cases with different numbers of re-assessments and to
control the effects of disease severity and depression as
well as correct for the drop-out over-time even in our
small sample. It also allowed us to accommodate varia-
tion in VPA intake over-time which is common feature of
its use as a therapy for co-morbid CNS disorders in
advanced HIV-infection.
Despite these limitations, the results highlight three
important points that have not been mentioned in any
related studies thus far and which should be factored into
subsequent trial designs. VPA may be detrimental:1) in
doses at the higher end of the therapeutic range, 2) over
prolonged periods, and 3) in patients with relatively
advanced HIV disease.
There are a number of potential explanations for the asso-
ciation between VPA and cognitive deterioration in
advanced HIV-infection observed here. It was originally
proposed that VPA had an adverse effect on HIV disease
by increasing HIV viral load but our results are not sup-
portive of this explanation [13]. Another possibility is that
VPA is having an adverse effect on mitochondria [14].
This is certainly known to be the case in children. Carni-
tine supplementation is recommended if VPA is used in
patients with mitochondrial disorders [15]. It is possible
therefore that VPA is detrimental to cognition through a
"triple hit" to mitochondria: HIV is known to affect mito-
chondrial function, some antiretrovirals also compromise
mitochondrial function, and VPA is known to impair
mitochondrial function. While these alone or in limited
combination may not be enough to disturb mitochon-
drial function the presence of all three may act additively
especially in those patients with the potential for limited
cognitive reserve.
Conclusion
Altogether, these results demonstrate that the hypothe-
sized neuroprotective effect of VPA mainly derived from
in vitro studies [7,16,17] should be considered with addi-
tional caution until larger studies are conducted. In future
clinical studies the sample size should be larger and
longer term with perhaps surrogate measures of brain
mitochondrial function (magnetic resonance spectros-
copy – MRS) included. The use and duration of the base-
line HAART regimen as well as probably the number of
brain penetrating antiretroviral drugs should be balanced
between treatment groups in order to control for a poten-
tial beneficial effect of HAART.
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